BidaskClub upgraded shares of AC Immune (NASDAQ:ACIU) from a hold rating to a buy rating in a report published on Wednesday morning.
Several other equities analysts have also recently commented on ACIU. Zacks Investment Research raised shares of AC Immune from a hold rating to a buy rating and set a $10.00 price target on the stock in a research report on Monday, August 6th. HC Wainwright set a $18.00 price target on shares of AC Immune and gave the stock a buy rating in a research report on Thursday, August 9th. ValuEngine cut shares of AC Immune from a buy rating to a hold rating in a research report on Monday, August 20th. Finally, Leerink Swann started coverage on shares of AC Immune in a research report on Monday, November 12th. They set an outperform rating and a $18.00 price target on the stock. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of Buy and a consensus target price of $15.25.
Shares of ACIU stock opened at $10.79 on Wednesday. AC Immune has a one year low of $7.16 and a one year high of $17.40.
Several hedge funds have recently modified their holdings of the company. GSA Capital Partners LLP bought a new position in shares of AC Immune during the third quarter worth about $110,000. JPMorgan Chase & Co. bought a new position in AC Immune in the third quarter worth about $142,000. Renaissance Technologies LLC lifted its holdings in AC Immune by 131.6% in the third quarter. Renaissance Technologies LLC now owns 52,300 shares of the company’s stock worth $418,000 after acquiring an additional 29,720 shares during the last quarter. Compagnie Lombard Odier SCmA lifted its holdings in AC Immune by 858.3% in the third quarter. Compagnie Lombard Odier SCmA now owns 33,539 shares of the company’s stock worth $268,000 after acquiring an additional 30,039 shares during the last quarter. Finally, Belpointe Asset Management LLC bought a new position in AC Immune in the third quarter worth about $400,000. 20.04% of the stock is currently owned by institutional investors and hedge funds.
AC Immune Company Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Read More: What is a balanced fund?
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.